Ursula Theuretzbacher

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

Evelina Tacconelli, Elena Carrara, Alessia Savoldi et al. · The Lancet Infectious Diseases · 2017 · 5.8K citations

Bacterial Resistance, Antimicrobial Drug Discovery, Antimicrobial Susceptibility +14

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni et al. · The Lancet Infectious Diseases · 2018 · 593 citations

Severe Infections, Health Sciences, Antibiotics +9

Pharmacokinetic/Pharmacodynamic Profile of Voriconazole

Ursula Theuretzbacher, Franziska Ihle, Hartmut Derendorf · Clinical Pharmacokinetics · 2006 · 464 citations

Pharmacological Study, Pharmacodynamics, Medicine +4

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

Roger L. Nation, Jian Li, Otto Cars et al. · The Lancet Infectious Diseases · 2014 · 331 citations

Microbial Toxin, Gastroenterology, Microbiology +8

Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women

Angela Huttner, Anna Kowalczyk, ‪Adi Turjeman‬‏ et al. · JAMA · 2018 · 200 citations · Full text